Sir, Pretransfusion tests are critical elements in transfusion safety and prevention of hemolytic transfusion reactions. Several methods are available for indirect antiglobulin test (IAT) to identify red cell antibodies and their titration including tube IAT with enhancement reagents, tubeless methods such as solid phase red cell adherence (SPRCA) tests, column agglutination test (CAT), microtiter -plate technique, and not routinely performed molecular tests. Implementation of automated techniques improves the standardization of methods and the quality of achieved results. [1] Since there is no routine method to evaluate the clinical significance of a single antibody, the only practical approach is to screen for the specificities of antibodies that usually lead to the accelerated clearance of antigen-positive red cells. [2] In our tertiary care facility, SPRCA technology was implemented (Galileo, fully automated immune hematology analyzer) for the routine pretransfusion testing with a combination of semiautomated testing on CAT (Biorad). Considering the recent knowledge about the clinical significance of reactive antibodies and suggestions to perform individual cost-benefit analysis in every institution, we decided to compare the sensitivity of SPRCA (automated) and CAT (manual) to detect clinically significant red cell antibodies in pretransfusion practice.
In a period of 32 months between August 01, 2013, and March 31, 2016, a total of 23,638 samples were tested for antibody screening and cross matching using CAT. In the last 3 months period between January and March 2016, a total of 1048 samples were tested for 3-cell antibody screen on SPRCA using capture RS3 (Galileo Immucor, Norcross, GA, USA) and positive samples were further subjected to identification.
In 29 months between August 2013 and December 2015, seven antibody positive results were found in 22,576 patients using CAT, while SPRCA detected nine antibody positive results out of 1048 which is statistically highly significant (P < 0.001). Of the seven positive patients by CAT, five were of only auto antibodies; both warm and cold and two patients showed a combination of auto-and allo-antibodies (one warm antibody with anti-E, anti-C and other cold antibody with anti-M allo-antibody). After implementing SPRCA, 9 out of 1048 patients showed positive screen in 3-month. Six of nine patients (67%) showed Rh antibodies of which three patients (33%) showed anti-D alloantibodies. 
Development of a National Thalassemia Policy in Pakistan
Sir, Thalassemia is the most prevalent genetic blood disorder in Pakistan [1] and a major healthcare challenge for the nation. It lays great psychological and financial stress on the affected families and is a huge burden on the national healthcare system. The thalassemia gene is restricted to affected families due to consanguineous marriages and is not randomly distributed. [2] Pakistan is seeing a large increase in thalassemic patients due to lack of any well-defined narrative or policy at the national level in the absence of which there are no national level prevention, control or management strategies. The National Safe Blood Transfusion Programme (SBTP) identified this strategic gap in the National Blood Policy and Strategic Framework [3] and requested the WHO for technical assistance to develop the National Thalassemia Policy.
To prepare the environment and learn about the views of the stakeholders for the need to have a national policy, the SBTP with the support from WHO organized three preliminary national consultations on the "Development of National Thalassemia Policy" in three major cities. [4] Representatives of the Thalassemia Federation of Pakistan and Thalassemia International Federation were especially invited to share their experience and provide an insight on the various issues concerning with thalassemia in Pakistan. The consultations were conducted with the prime objective to hold debate on a range of aspects of thalassemia and ascertain the views of the stakeholders and reach a consensus on different aspects of thalassemia including prevention, control strategies, management guidelines, prenatal and routine diagnosis, uniform and effective legislation, communication strategies, transfusion protocols, and research and development.
For the formulation of the actual policy, the services of an international expert, well familiar with thalassemia and blood safety issues, stakeholders and the Pakistan scenario, will be procured by the WHO. The expert will visit Pakistan to conduct a rapid situational analysis, hold individual interactions, focus group discussions, identify issues for priority, and help develop consensus on all key issues. The draft developed by the international consultant will be finalized after a second round of national consultations. The implementation of the policy, outlined in the document, will be through the federal and provincial health departments and the NGO sector. On the basis of this National Thalassemia Policy, an action plan will be developed. These consensus documents will then be presented to the Ministry of National Health Services, which is already facilitating this initiative, for the government's endorsement and implementation.
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